Literature DB >> 413831

Purification and properties of human pancreatic deoxyribonuclease I.

A Funakoshi, Y Tsubota, H Wakasugi, H Ibayashi, Y Takagi.   

Abstract

Human pancreatic DNase I was purified extensively from duodenal juice of healthy subjects by a procedure including ammonium sulfate fractionation, ethanol fractionation, phosphocellulose fractionation, isoelectric focusing, and gel filtration. The final preparation was free of DNase II, pancreatic RNase, alkaline phosphatase, and protease. The enzyme had a molecular weight of approximately 30,000, as determined by gel filtration on Sephadex G-100, and showed maximum activity at pH 7.2-7.6. It required divalent cations for activity, and caused single-strand breaks by endonucleolytic attack on double- as well as single-stranded DNA molecules. The enzyme was inhibited by actin and bovine pancreatic DNase I antibody.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 413831     DOI: 10.1093/oxfordjournals.jbchem.a131875

Source DB:  PubMed          Journal:  J Biochem        ISSN: 0021-924X            Impact factor:   3.387


  11 in total

1.  Clinical investigation of serum deoxyribonuclease: I. Analysis of serum deoxyribonuclease activity in comparison with normal and after endoscopic retrograde pancreatography.

Authors:  A Funakoshi; T Kimura; H Wakasugi; H Ibayashi
Journal:  Gastroenterol Jpn       Date:  1979-10

2.  Rabbit DNase I: purification from urine, immunological and proteochemical characterization, nucleotide sequence, expression in tissues, relationships with other mammalian DNases I and phylogenetic analysis.

Authors:  T Yasuda; H Takeshita; T Nakajima; O Hosomi; Y Nakashima; K Kishi
Journal:  Biochem J       Date:  1997-07-15       Impact factor: 3.857

3.  Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum.

Authors:  S Shak; D J Capon; R Hellmiss; S A Marsters; C L Baker
Journal:  Proc Natl Acad Sci U S A       Date:  1990-12       Impact factor: 11.205

Review 4.  Assessment and significance of protein-protein interactions during development of protein biopharmaceuticals.

Authors:  Sandeep Yadav; Jun Liu; Thomas M Scherer; Yatin Gokarn; Barthélemy Demeule; Sonoko Kanai; James D Andya; Steven J Shire
Journal:  Biophys Rev       Date:  2013-03-14

5.  Biochemical and clinical studies on human pancreatic deoxyribonuclease I inhibitor.

Authors:  A Funakoshi; H Wakasugi; M Nakamura; Y Takagi; H Ibayashi
Journal:  Gastroenterol Jpn       Date:  1980

6.  The inhibition of bovine and rat parotid deoxyribonuclease I by skeletal muscle actin. A biochemical and immunocytochemical study.

Authors:  H G Mannherz; V Kreuder; J Koch; J Dieckhoff; D Drenckhahn
Journal:  Biochem J       Date:  1982-11-01       Impact factor: 3.857

7.  Clinical studies on human pancreatic deoxyribonuclease I.

Authors:  A Funakoshi; Y Tsubota; H Wakasugi; H Ibayashi; Y Takagi
Journal:  Gastroenterol Jpn       Date:  1979

8.  A radial diffusion assay for plasma and serum deoxyribonuclease I.

Authors:  S Chitrabamrung; J S Bannett; R L Rubin; E M Tan
Journal:  Rheumatol Int       Date:  1981       Impact factor: 2.631

9.  Genetic polymorphism of human urine deoxyribonuclease I.

Authors:  K Kishi; T Yasuda; S Awazu; K Mizuta
Journal:  Hum Genet       Date:  1989-02       Impact factor: 4.132

10.  Clinical investigation of serum deoxyribonuclease: II. Clinical studies of serum deoxyribonuclease activity in pancreatic disease.

Authors:  A Funakoshi; H Wakasugi; H Ibayashi
Journal:  Gastroenterol Jpn       Date:  1979-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.